title: Relationship between urinary tract infection categorization and pathogens' antimicrobial susceptibilities.
abstract: BACKGROUND
  Urinary tract infections (UTIs) can be hard to treat and treatment plans need to include accurate categorization such as uncomplicated or complicated UTI, or catheterized or uncatheterized UTI. We investigated the antibiotic susceptibilities of representative uropathogens in UTI categories.
  
  
  METHODS
  We isolated uropathogens and analyzed their antimicrobial susceptibilities according to UTI categorization such as: (1) urology outpatients, urology inpatients, or other department inpatients; (2) uncomplicated or complicated UTIs; (3) upper or lower UTIs, and (4) non-catheterized or catheterized UTIs.
  
  
  RESULTS
  Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa were representative uropathogens. Susceptibilities to levofloxacin (LVFX) in E. coli in urology outpatients (p = 0.0179), those to ceftadizime in E. coli in other department inpatients (p = 0.0327), and those to LVFX in E. faecalis in complicated UTI (p = 0.0137) significantly decreased in these 3 years compared with the previous 3 years. Susceptibilities of upper UTI to LVFX in E. coli were significantly lower in the recent 4 years compared to lower UTI (p = 0.0452) and those of catheterized UTI to LVFX in E. faecalis were significantly lower than in non-catheterized UTI (p = 0.0153).
  
  
  CONCLUSIONS
  Data demonstrated different tendencies of uropathogens' antibiotic susceptibilities according to UTI categorizations and they could be useful for planning UTI treatments.
authors.affiliation: Division of Urology, Department of Organs Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
authors.forename: Fukashi
authors.initials: F
authors.lastname: Yamamichi
authors.forename: Katsumi
authors.initials: K
authors.lastname: Shigemura
authors.forename: Minori
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Nakano
authors.forename: Kazushi
authors.initials: K
authors.lastname: Tanaka
authors.forename: Soichi
authors.initials: S
authors.lastname: Arakawa
authors.forename: Masato
authors.initials: M
authors.lastname: Fujisawa
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use*; D055499:Catheter-Related Infections / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology*; D002442:Ceftazidime / Q000627:therapeutic use; D013293:Enterococcus faecalis / Q000187:drug effects / Q000472:pathogenicity; D004926:Escherichia coli / Q000187:drug effects / Q000472:pathogenicity; D006801:Humans; D007297:Inpatients / Q000145:classification*; D007564:Japan; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000627:therapeutic use; D010045:Outpatients / Q000145:classification*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000472:pathogenicity; D013997:Time Factors; D014546:Urinary Catheterization / Q000009:adverse effects / Q000145:classification*; D014552:Urinary Tract Infections / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology*; D014573:Urology Department, Hospital / Q000145:classification
chemical_list: D000890:Anti-Infective Agents; D064704:Levofloxacin; D002442:Ceftazidime; D015242:Ofloxacin